Validating visual evoked potentials as a preclinical, quantitative biomarker for remyelination efficacy.

ABSTRACT: Many biomarkers in clinical neuroscience lack pathological certification. This issue is potentially a significant contributor to the limited success of neuroprotective and neurorestorative therapies for human neurological disease-and is evident even in areas with therapeutic promise such as myelin repair. Despite the identification of promising remyelinating candidates, biologically validated methods to demonstrate therapeutic efficacy or provide robust preclinical evidence of remyelination in the CNS are lacking. Therapies with potential to remyelinate the CNS constitute one of the most promising and highly anticipated therapeutic developments in the pipeline to treat multiple sclerosis and other demyelinating diseases. The optic nerve has been proposed as an informative pathway to monito

SUBMITTER: Cordano C 

PROVIDER: S-EPMC10200282 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature